title: [Recombinant alpha2-interferon substances in treating patients with acute hepatitis B with a mild course].
abstract: Interferon (viferon-500 and reaferon) is recommended for patients with light forms of acute virus hepatitis B to prevent chronic degeneration of the disease. The data of dynamic monitoring of the production of alpha-interferon helped develop a test for predicting threatened chronic degeneration of light forms of hepatitis B. Indications for antiviral therapy aimed at prevention of chronic disease have been defined.
authors.forename: V V
authors.initials: VV
authors.lastname: Malinovskaia
authors.forename: M V
authors.initials: MV
authors.lastname: Neumoina
authors.forename: G S
authors.initials: GS
authors.lastname: Bragina
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D006509:Hepatitis B / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D011994:Recombinant Proteins
chemical_list: D007370:Interferon Type I; D011994:Recombinant Proteins